Bart L. Scott

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

Bart L. Scott, Marcelo C. Pasquini, Brent R. Logan et al. · Journal of Clinical Oncology · 2017 · 666 citations · Full text

Medicine, Hematology, Oncology +16

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease

Christopher S. Hourigan, Laura W. Dillon, Gege Gui et al. · Journal of Clinical Oncology · 2019 · 442 citations · Full text

Medicine, Hematology, Oncology +17

Comorbidity and Disease Status–Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation

Mohamed L. Sorror, Brenda M. Sandmaier, Barry E. Storer et al. · Journal of Clinical Oncology · 2007 · 400 citations · Full text

Medicine, Hematology, Hematologic Oncology +15

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis

Bart L. Scott, Brenda M. Sandmaier, Barry E. Storer et al. · Leukemia · 2005 · 233 citations

Medicine, Hematology, Oncology +16

Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis

Celalettin Üstün, Andreas Reiter, Bart L. Scott et al. · Journal of Clinical Oncology · 2014 · 185 citations · Full text

Medicine, Hematology, Immunology +17